Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Direct Targeting of MYC/MAX DNA-binding with a Programmable Synthetic Transcriptional Repressor Platform

ABSTRACT: SILAC proteomics data analysis of P493-6 cells treated with synthetic transcriptional repressors.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Raymond Moellering

PROVIDER: MSV000089749 | MassIVE | Tue Jun 28 09:07:00 BST 2022

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Similar Datasets

The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYC.

Project description: Not available

| S-EPMC3460914 | biostudies-literature

Dynamic equilibrium on DNA defines transcriptional regulation of a multidrug binding transcriptional repressor, LmrR.

Project description: Not available

| S-EPMC5428041 | biostudies-literature

The transcriptional repressor activator protein Rap1p is a direct regulator of TATA-binding protein.

Project description: Not available

| S-EPMC2417159 | biostudies-literature

Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains.

Project description: Not available

| S-EPMC3556390 | biostudies-literature

Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7

Project description:Synthetic lethal CRISPR screen in MCF10A FBXW7 isogenic models

2023-05-22 | E-MTAB-12939 | biostudies-arrayexpress

Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.

Project description: Not available

| S-EPMC6895415 | biostudies-literature

Non-equilibrium repressor binding kinetics link DNA damage dose to transcriptional timing within the SOS gene network.

Project description: Not available

| S-EPMC5999292 | biostudies-literature

Synthetic introns enable mutation-dependent targeting of cancer cells

Project description:Many cancers carry recurrent change-of-function mutations in RNA splicing factor genes, which induce sequence-specific changes in RNA splicing. Here, we describe a method to harness this change in RNA splicing activity to drive splicing factor mutation-dependent gene expression in cancers and selectively eliminate these tumors. We engineered synthetic introns which were efficiently spliced in leukemia and breast epithelial cells bearing the most common SF3B1 mutations, but unspliced in wild-type cells—and vice versa—to yield mutation-dependent protein production. A massively parallel screen of 8,881 distinct introns delineated ideal intronic size, mapped essential sequence elements, and revealed the basis of mutation-dependent splicing. Synthetic introns enabled mutation-dependent expression of herpes simplex virus thymidine kinase and subsequent ganciclovir-mediated elimination of leukemia and breast epithelial cells bearing SF3B1 mutations, while leaving wild-type cells unaffected. This approach significantly decreased the growth of otherwise lethal leukemia xenografts and correspondingly improved host survival. The modular, compact, and specific nature of synthetic introns thereby provide a means to exploit cancer-specific changes in RNA splicing for genotype-dependent gene expression and gene therapy.

2021-12-30 | GSE163217 | GEO

Transcriptional control of DNA replication licensing by Myc.

Project description: Not available

| S-EPMC3853707 | biostudies-literature

Direct transcriptional control of the Dpp target omb by the DNA binding protein Brinker.

Project description: Not available

| S-EPMC305821 | biostudies-literature